ASTRAZENECA - Seroquel XR: Para IV Settled with Handa, More to come
AstraZeneca today announced that it has settled paragraph IV litigation for Seroquel XR with Handa pharmaceuticals, who has the first to filer status with 180 days exclusivity. As per the settlement Handa will launch Seroquel XR generics only after November 2016. While litigation is ongoing with other Para-IV filers and a court decision is due. Accord Healthcare – a subsidiary of India based Intas pharmaceuticals has also received tentative approval and poses the most significant threat as the 30-month stay has expired and a court decision should be around the corner. There is a possibility that AZN might settle with Accord as well. The NCE exclusivity of …
COMPANIES MENTIONED
ASTRAZENECA
ASTRAZENECA
